

# Annual General Meeting of Ipsen S.A. of 13 May 2026

## Voting results

PARIS, FRANCE, 20 MAY 2026

Number of shares comprising the capital	83,814,526
Number of shares with voting rights	82,417,092
Number of shareholders present, represented or voting by mail	3,196
Number of shares held by shareholders present, represented or voting by mail	72,443,213
Number of votes held by shareholders present, represented or voting by mail	120,173,912
Quorum	87.90%

Resolutions	Votes cast				Votes not validly cast	Present & Represented		Total Shares cast		Result
	For	%	Against	%		Shares	Votes	Shares	Capital %	
<b>As an Ordinary Annual General Meeting</b>										
1. Approval of the annual financial statements for the financial year ending 31 December 2025	119,923,793	99.92%	99,093	0.08%	150,601	72,442,788	120,173,487	72,292,212	86.25%	<b>Adopted</b>
2. Approval of the consolidated financial statements for the financial year ending on 31 December 2025	119,970,136	99.96%	52,750	0.04%	150,601	72,442,788	120,173,487	72,292,212	86.25%	<b>Adopted</b>
3. Allocation of the results for the 2025 financial year and setting of the dividend at €1.60 per share	120,169,379	>99.99%	797	<0.01%	3,311	72,442,788	120,173,487	72,439,502	86.43%	<b>Adopted</b>
4. Special report of the statutory auditors on regulated agreements – Finding of absence of new agreement	120,166,039	>99.99%	2,915	<0.01%	4,533	72,442,788	120,173,487	72,438,722	86.43%	<b>Adopted</b>
5. Renewal of the term of office of HIGHROCK S.à.r.l as a Director	108,905,733	90.66%	11,217,177	9.34%	50,577	72,442,788	120,173,487	72,392,471	86.37%	<b>Adopted</b>
6. Renewal of the term of office of Mr. Pascal TOUCHON as a Director	118,491,682	98.65%	1,621,599	1.35%	60,206	72,442,788	120,173,487	72,386,249	86.36%	<b>Adopted</b>
7. Renewal of the term of office of Mr. Piet WIGERINCK as a Director	114,833,308	95.56%	5,334,842	4.44%	5,337	72,442,788	120,173,487	72,437,921	86.43%	<b>Adopted</b>
8. Co-optation of Mr. Peter GUENTER as a Director, in replacement of late Henri BEAUFOUR	108,166,951	90.01%	12,001,901	9.99%	4,635	72,442,788	120,173,487	72,438,413	86.43%	<b>Adopted</b>
9. Approval of the compensation policy applicable to the members of the Board of Directors	119,980,183	99.84%	187,461	0.16%	5,843	72,442,788	120,173,487	72,437,010	86.43%	<b>Adopted</b>
10. Approval of the compensation policy applicable to the Chairman of the Board of Directors	119,347,272	99.32%	821,385	0.68%	4,830	72,442,788	120,173,487	72,438,023	86.43%	<b>Adopted</b>

11. Approval of the compensation policy applicable to the Chief Executive Officer and/or any other executive officer	98,295,204	81.84%	21,816,590	18.16%	61,693	72,442,788	120,173,487	72,384,357	86.36%	<b>Adopted</b>
12. Approval of the information relating to the compensation of corporate officers referred to in I of Article L.22-10-9 of the French Commercial Code	118,207,516	98.90%	1,316,967	1.10%	649,004	72,442,788	120,173,487	71,794,291	85.66%	<b>Adopted</b>
13. Approval of the base, variable and exceptional elements making up the total compensation and the benefits of any kind paid during the past financial year or granted for the same financial year to Mr. Marc de GARIDEL, Chairman of the Board of Directors	119,360,494	99.33%	807,728	0.67%	5,265	72,442,788	120,173,487	72,437,768	86.43%	<b>Adopted</b>
14. Approval of the base, variable and exceptional elements making up the total compensation and the benefits of any kind paid during the past financial year or granted for the same financial year to Mr. David LOEW, Chief Executive Officer	111,909,261	93.46%	7,834,583	6.54%	429,643	72,442,788	120,173,487	72,016,617	85.92%	<b>Adopted</b>
15. Authorization to be given to the Board of Directors to allow the Company to repurchase its own shares pursuant to the provisions of article L.22-10-62 of the French Commercial Code	119,994,493	99.87%	159,391	0.13%	19,603	72,442,788	120,173,487	72,423,420	86.41%	<b>Adopted</b>
<b>As an Extraordinary Annual General Meeting</b>										
16. Authorization to be given to the Board of Directors to carry out free grants of shares to salaried staff members and/or certain corporate officers of the Company or affiliated companies or economic interest groups	100,500,001	83.64%	19,660,577	16.36%	13,334	72,443,213	120,173,912	72,433,101	86.42%	<b>Adopted</b>
17. Amendment to Article 10.3 of the Articles of Association to modernize and simplify the notification procedures applicable to the crossing of statutory thresholds	120,153,679	99.99%	15,561	0.01%	4,672	72,443,213	120,173,912	72,438,776	86.43%	<b>Adopted</b>

18. Alignment of Article 24.3 of the Articles of Association with respect to the record date for participating in the Annual General Meeting	120,167,950	>99.99%	84	<0.01%	5,878	72,443,213	120,173,912	72,437,603	86.43%	<b>Adopted</b>
<b>As an Ordinary Annual General Meeting</b>										
19. Powers to carry out formalities	120,167,911	>99.99%	84	<0.01%	5,492	72,442,788	120,173,487	72,437,644	86.43%	<b>Adopted</b>

### About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit [ipсен.com](http://ipсен.com).

### Ipsen Contacts

#### Investors

Henry Wheeler  
Khalid Deojee

[henry.wheeler@ipсен.com](mailto:henry.wheeler@ipсен.com)  
[khalid.deojee@ipсен.com](mailto:khalid.deojee@ipсен.com)

+33 7 66 47 11 49  
+33 6 66 01 95 26

#### Media

Sally Bain  
Anne Liontas

[sally.bain@ipсен.com](mailto:sally.bain@ipсен.com)  
[anne.liontas.ext@ipсен.com](mailto:anne.liontas.ext@ipсен.com)

+1 857 320 0517  
+33 7 67 34 72 96

### Disclaimers and/or forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on [ipсен.com](http://ipсен.com).